{"id":4654,"date":"2019-04-04T12:59:15","date_gmt":"2019-04-04T07:29:15","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4654"},"modified":"2021-07-24T12:57:17","modified_gmt":"2021-07-24T07:27:17","slug":"the-business-cocktail-59","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59","title":{"rendered":"AgomAb Therapeutics raises $23.5M; Allergan&#8217;s eye drug; Good news for the patients; Dyne Therapeutics comes to life"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f6de9f92f90\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f6de9f92f90\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59\/#AgomAb_Therapeutics_raises_USD_235_million_for_its_agomAbs\" >AgomAb Therapeutics\nraises USD 23.5 million for its agomAbs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59\/#Allergans_eye_drug_Abicipar_fails\" >Allergan&#8217;s eye drug Abicipar fails<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59\/#Good_news_for_the_patients_suffering_from_Type-I_diabetes\" >Good news for the\npatients suffering from Type-I diabetes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59\/#Dyne_Therapeutics_comes_to_life\" >Dyne Therapeutics comes to life<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AgomAb_Therapeutics_raises_USD_235_million_for_its_agomAbs\"><\/span><strong>AgomAb Therapeutics\nraises USD 23.5 million for its agomAbs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">A Belgian biotherapeutics company <strong>AgomAb<\/strong> <strong>Therapeutics <\/strong>which has been in a long run of making <strong>agonistic antibodies <\/strong>has secured <strong>USD 23.5 million <\/strong>in a Series A financing round from international investor syndicate co-led by V-Bio Ventures (Belgium) and Advent France Biotechnology (France), and joined by <strong>Boehringer Ingelheim Venture Fund<\/strong> (Germany), <strong>Omnes<\/strong> (France) and <strong>Pontifax<\/strong> (Israel). <strong>Agonistic monoclonal antibodies<\/strong> (agomAbs) can potentially treat a variety of fibrotic, <strong>inflammatory<\/strong>, <strong>autoimmune<\/strong> and <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/degenerative-disc-disease-pipeline-insight\">degenerative<\/a><\/strong> diseases.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Allergans_eye_drug_Abicipar_fails\"><\/span><strong>Allergan&#8217;s eye drug<\/strong> <strong>Abicipar fails<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">Considered one of the six stars Allergan\u2019s <a href=\"https:\/\/www.delveinsight.com\/report-store\/eye-infections-market\">EYE <\/a>drug \u2018Abicipar\u2019 was considered an equivalent to <strong>Novartis\u2019s Lucentis <\/strong>(ranibizumab), but the least promising results during the trials and 15% inflammatory chances reduced to 8.9% &nbsp;have dwindled the faith of &nbsp;Wall Street analysts. In a road ahead, Allergan plans to file a Biologics License Application by the end of June.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Good_news_for_the_patients_suffering_from_Type-I_diabetes\"><\/span><strong>Good news for the\npatients suffering from Type-I diabetes <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\">With <strong>Insulin<\/strong> prices skyrocketing and the mounting public pressure, the insurance giant <strong>Cigna<\/strong> and its drug benefit arm, <strong>Express<\/strong> <strong>Scripts<\/strong>, has decided to reduce the price of insulin from <strong>USD 40 to USD 25 per<\/strong> <strong>month<\/strong>, on an average. The reduction of out-of-pocket costs of the lifesaving drug would help save money and result in patients not cutting on their <a href=\"https:\/\/www.delveinsight.com\/report-store\/insulin-resistance-market\"><strong>Insulin<\/strong> <\/a>dosage. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dyne_Therapeutics_comes_to_life\"><\/span><strong>Dyne<\/strong> <strong>Therapeutics comes to life<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background has-very-light-gray-background-color\"><strong>Dyne Therapeutics<\/strong> founded, seeded and incubated by the <strong>Life science VC Atlas Venture<\/strong> and has raised <strong>USD 50 million<\/strong> series A funding from <strong>Amgen<\/strong>, <strong>Editas<\/strong> <strong>Medicine<\/strong>, <strong>Merck,<\/strong> <g class=\"gr_ gr_5 gr-alert gr_gramm gr_inline_cards gr_run_anim Punctuation only-ins replaceWithoutSep\" id=\"5\" data-gr-id=\"5\">and<\/g> <strong>Sarepta<\/strong> <strong>Therapeutics<\/strong>. Dyne will be solely focused on antibody conjugates to deliver nucleic acids and other molecules for the treatment of serious muscle diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AgomAb Therapeutics raises USD 23.5 million for its agomAbs A Belgian biotherapeutics company AgomAb Therapeutics which has been in a long run of making agonistic antibodies has secured USD 23.5 million in a Series A financing round from international investor syndicate co-led by V-Bio Ventures (Belgium) and Advent France Biotechnology (France), and joined by Boehringer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4664,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[3082,3080,3081,70,831,3083,3084,17276,2574,1103,395,2700,3085],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-4654","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abicipar","tag-agomab","tag-agonistic-monoclonal-antibodies","tag-allergan","tag-amgen","tag-cigna","tag-dyne-therapeutics","tag-editas-medicine","tag-insulin","tag-lucentis","tag-merck","tag-usd","tag-vc-atlas-venture","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AgomAb Therapeutics raises $23.5M; Allergan&#039;s eye drug<\/title>\n<meta name=\"description\" content=\"the insurance giant Cigna and its drug benefit arm, Express Scripts, has decided to reduce the price of insulin from USD 40 to USD 25 per month...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AgomAb Therapeutics raises $23.5M; Allergan&#039;s eye drug\" \/>\n<meta property=\"og:description\" content=\"the insurance giant Cigna and its drug benefit arm, Express Scripts, has decided to reduce the price of insulin from USD 40 to USD 25 per month...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-04T07:29:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09173016\/My-Post-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AgomAb Therapeutics raises $23.5M; Allergan's eye drug","description":"the insurance giant Cigna and its drug benefit arm, Express Scripts, has decided to reduce the price of insulin from USD 40 to USD 25 per month...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59","og_locale":"en_US","og_type":"article","og_title":"AgomAb Therapeutics raises $23.5M; Allergan's eye drug","og_description":"the insurance giant Cigna and its drug benefit arm, Express Scripts, has decided to reduce the price of insulin from USD 40 to USD 25 per month...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-04T07:29:15+00:00","article_modified_time":"2021-07-24T07:27:17+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09173016\/My-Post-2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59","name":"AgomAb Therapeutics raises $23.5M; Allergan's eye drug","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09173016\/My-Post-2.jpg","datePublished":"2019-04-04T07:29:15+00:00","dateModified":"2021-07-24T07:27:17+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"the insurance giant Cigna and its drug benefit arm, Express Scripts, has decided to reduce the price of insulin from USD 40 to USD 25 per month...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-59#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09173016\/My-Post-2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09173016\/My-Post-2.jpg","width":2560,"height":1440,"caption":"the business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09173016\/My-Post-2-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Abicipar<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AgomAb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Agonistic monoclonal antibodies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cigna<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dyne Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Editas Medicine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">insulin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lucentis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">VC Atlas Venture<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abicipar<\/span>","<span class=\"advgb-post-tax-term\">AgomAb<\/span>","<span class=\"advgb-post-tax-term\">Agonistic monoclonal antibodies<\/span>","<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Cigna<\/span>","<span class=\"advgb-post-tax-term\">Dyne Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Editas Medicine<\/span>","<span class=\"advgb-post-tax-term\">insulin<\/span>","<span class=\"advgb-post-tax-term\">Lucentis<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">USD<\/span>","<span class=\"advgb-post-tax-term\">VC Atlas Venture<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 4, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 4, 2019 12:59 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4654"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4654\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4664"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4654"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4654"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}